[1] Forner A, Reig ME, de Lope CR, et al.Current strategy for staging and treatment: the BCLC update and future prospects[J].Semin Liver Dis,2010,30(1):61-74.
[2] Boulin M, Delhom E, Pierredon-Foulongne MA, et al.Transarterial chemoembolization for hepatocellular carcinoma: An old method, now flavor of the day[J].Diagn Interv Imaging,2015,96(6):607-615.
[3] Idee, JM and Guiu B.Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review[J].Crit Rev Oncol Hematol,2013,88(3):530-549.
[4] Dodds HM, Walpole ET, Rivory LP, et al. Disposition of epirubicin after intraarterial administration in Lipiodol to patients with hepatocellular carcinoma[J].Ther Drug Monit, 1996,18(5): 537-543.
[5] 余磊,唐璠,曹志伟,等.颗粒型栓塞材料治疗原发性肝癌的临床疗效及安全性分析[J].介入放射学杂志,2020,29(09):900-906.
[6] Takayasu K, Arii S, Ikai I, et al.Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis[J].AJR Am J Roentgenol,2010,194(3): 830-837.
[7] 陈广,贺文,马大庆, 等.明胶海绵微粒对动脉化疗栓塞术后肝癌瘤组织CT灌注参数的影响[J].山西医药杂志,2010,39(13):585-588.
[8] 许敏.明胶海绵颗粒在原发性肝癌灌注化疗栓塞中疗效观察[J].介入放射学杂志,2018,27(12):1155-1159.
[9] Chen S, Yu W, Zhang K, et al.Transarterial chemoembolization for unresectable hepatocellular carcinoma: A comparison of the efficacy and safety of 2 embolic agents[J].Medicine (Baltimore),2018,97(21): e10832.
[10] Laurent A.Microspheres and nonspherical particles for embolization[J].Tech Vasc Interv Radiol,2007,10(4):248-256.
[11] Hong K, Kobeiter H, Georgiades CS, et al.Effects of the type of embolization particles on carboplatin concentration in liver tumors after transcatheter arterial chemoembolization in a rabbit model of liver cancer[J].J Vasc Interv Radiol,2005,16(12): 1711-1717.
[12] Gupta S, Wright KC, Ensor J, et al.Hepatic arterial embolization with doxorubicin-loaded superabsorbent polymer microspheres in a rabbit liver tumor model[J].Cardiovasc Intervent Radiol,2011,34(5):1021-1030.
[13] Huang K, Zhou Q, Wang R, et al.Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma[J].J Gastroenterol Hepatol,2014,29(5):920-925.
[14] Lammer J, Malagari K, Vogl T, et al.Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study[J].Cardiovasc Intervent Radiol,2010,33(1):41-52.
[15] Megias Vericat JE.Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs[J].Radiologia,2015,57(6):496-504.
[16] 官泳松,贺庆,靳勇, 等.迦俐生聚乙烯醇栓塞微球的研制[J].中华肝脏病杂志,2016,24(7):549-551.
[17] Zhang S, Huang C, Li Z, et al.Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers[J].Drug Deliv,2017,24(1):1011-1017.
[18] 陈刚,张鼎,应亚草, 等.国产载药微球经动脉化疗栓塞治疗不可切除原发性肝癌的临床研究[J].浙江大学学报(医学版),2017,46(1):44-51.
[19] 刘金,曹刚,张根山, 等.国产CalliSpheres载药微球治疗原发性肝癌12例[J].介入放射学杂志,2017,26(11):993-998.
[20] Edeline J, Gilabert M, Garin E, et al.Yttrium-90 microsphere radioembolization for hepatocellular carcinoma[J].Liver Cancer,2015,4(1):16-25.
[21] 王斯妮,贾中芝,胡红杰, 等.钇-90微球的特性、放射栓塞的操作技术及安全防护——钇-90微球放射栓塞系列回顾(一)[J].介入放射学杂志,2017,26(10):952-958.
[22] Zhang Y, Li Y, Ji H, et al.Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma[J].A meta-analysis. Biosci Trends,2015,9(5):289-298. |
2020, Vol. 37 
